← All trials
NCT06252220
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2024
- Primary completion
- Dec 14, 2024
- Completion date
- Jun 30, 2025
- First posted
- Feb 9, 2024
- Last posted
- Apr 22, 2024
- Enrollment
- 81
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NeuroBo PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.